2 completed, 2 not yet recruiting, 1 recruiting, 1 withdrawn. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Not yet recruiting 2, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Not yet recruiting 1, Withdrawn 1 |
Follow Advanced Triple-Negative Breast Cancer: new trials by email Literature Review of Advanced Triple-Negative Breast Cancer trials Research Report on Advanced Triple-Negative Breast Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Zn-Telomir - Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Telomir Pharmaceuticals, Inc. | 76 | 2026-10-01 | 2026-06-23 |
| Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer Sacituzumab Govitecan (SG), Atropine, G-CSF (Granulocyte colony-stimulating factor) - Breast Cancer, Advanced HR+/HER2- Breast Cancer | Phase 2 | Not yet recruiting | MedSIR | 30 | 2026-07-01 | 2026-01-28 |
| Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer. Adebrelimab + VEX metronomic chemotherapy + radiotherapy, Adebrelimab + VEX metronomic chemotherapy - Advanced Triple-negative Breast Cancer | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 150 | 2024-09-10 | 2026-06-10 |
| A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer BEBT-209 capsules, Carboplatin injection, Gemcitabine hydrochloride for injection - Advanced Triple-Negative Breast Cancer | Phase 2 | Completed | BeBetter Med Inc | 65 | 2023-04-12 | 2026-08-18 |
| Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer Vinorelbine, Apatinib - Advanced Triple-Negative Breast Cancer | Phase 2 | Completed | Fudan University | 66 | 2017-08-16 | 2022-04-20 |
| A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer ONC201 - Advanced Glioblastoma, Advanced Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | Jazz Pharmaceuticals | 2014-01-01 | 2021-04-30 |
Breast Neoplasms (2) · Triple Negative Breast Neoplasms (1)
Breast Diseases (2) · Neoplasms (2) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Atropine (1) · Carboplatin (1) · Filgrastim (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1) · Injections (1) · Radiotherapy (1) · TIC10 compound (1) · Vinorelbine (1) · apatinib (1) · sacituzumab govitecan (1)
BeBetter Med Inc (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · Jazz Pharmaceuticals (1) · MedSIR (1) · Telomir Pharmaceuticals, Inc. (1)
China (3) · United States (1)
Jason Faris, MD (1) · Qiang Liu, Phd (1) · Quchang Ouyang, Phd (1) · Xichun Hu, MD, PhD (1)
2025 (1)